drugset / Trial / NCT05713110
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase (phase IIb).
Timeline
- Start
- 2023-02-13
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMDIZALISIB | Small molecule | 20 mg | Oral |
| Subject | AMDIZALISIB | Small molecule | 30 mg | Oral |
| Subject | Tazemetostat | Small molecule | 800 mg | Oral |